

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.
Stanford Research Park
700 Hansen Way
Palo Alto, CA 94304

Telephone
(650) 849-6600

Facsimile
(650) 849-6666

FACSIMILE TRANSMITTAL

TO

Name: Examiner William Moore
Firm: U.S. Patent and Trademark Office
Fax No.: 703-746-3169
Phone No.: 703-308-0583
Subject: Information Disclosure
Statement
Your File No.: 08/485,438

FROM

Name: M. Paul Barker
Phone No.: 650-849-6620
Fax # Verified by: L. Matsumi
Pages (incl. this): 38
Date: August 26, 2003
Our File No.: 04189.084-03000

Confirmation Copy to Follow: No

Message:

U.S. Patent Application Serial No. 08/485,438
Filed: June 7, 1995
In re Application of: Eisenberg et al.
For: INHIBITION OF RETROVIRUS INFECTION

We enclose:

1. Information Disclosure Statement (2 pages);
2. Form PTO 1449 (1 page); and
3. Copies of 5 documents.

If there is a problem with this transmission, notify fax room at (650) 849-6600 or the sender at the number above.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

PATENT

Customer Number: 22,852

Attorney Docket No. 4189.0084-03000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eisenberg et al.

Application No.: 08/485,438

Filed: June 7, 1995

For: INHIBITION OF RETROVIRUS
INFECTION

Group Art Unit: 1652

Examiner: Moore, W.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or an action that otherwise closes prosecution. Under the provisions of 37 C.F.R. § 1.97(c), please charge the Information Disclosure Statement fee of \$180.00 as specified by Section 1.17(p) to Deposit Account No. 06-0916.

Copies of the listed documents other than the seven United States patents are attached. Examiner Moore informed the undersigned in a telephone discussion today that he need not submit copies of the United States patents, because Examiner Moore will print them out himself.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNN LLP
1100 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 26, 2003

By: 

M. Paul Barker
Reg. No. 32,013

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com